Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal cytarabine-daunorubicin vs 7+3 in older high-risk AML
NCT06182592Phase 3Not yet recruiting
- Sponsor
- CSPC Zhongnuo Pharmaceutical
- Start
- Jan 2024
- Primary completion
- Feb 2026
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
A Phase 3 trial of daunorubicin + cytarabine liposome in acute myeloid leukemia (AML), sponsored by CSPC Zhongnuo Pharmaceutical. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
daunorubicin + cytarabine liposome
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06182592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06182592.